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Experimental "allergic" encephalomyelitis (EAE), produced by the injection 
of brain-containing vaccines, has been studied for many decades (1, 2). In the 
earliest studies no adjuvants were used, and in the human counterpart which 
still  occurs,  rabies  post-vaccinal  encephalomyelitis,  no  known  adjuvant  is 
involved.  In  later  experiments,  even  with  adjuvants  such  as  heterologous 
serum, repeated injections over many months resulted in disease which was 
quite irregular in incidence and severity (1,  2).  The histologic changes with 
characteristic demyelinization were best demonstrated in the central nervous 
system of monkeys by Rivers et al. (3, 4), but the long incubation period made 
further refinements in the definition of etiology or pathogenesis impractical. 
The development by Freund et al.  (5-7)  of adjuvants capable of regularly 
inducing delayed sensitivity to a variety of antigens renewed interest in EAE, 
since it could be readily produced in a high percentage of experimental animals 
within a few weeks after only one or a few injections (8-16). The effect of these 
adjuvants, killed mycobacterla in water-in-oil emulsion, is further potentiated 
by the use  of the  intracutaneous route  (17-20)  and, in  some  species,  by a 
"priming" injection of killed ttemophilus pertussis (19, 20). 
Opinions have differed, however, concerning the relative importance of these 
adjuvants; indeed, some reports have indicated that even the brain need not 
be included in the encephalitogenic emulsion (21-24).  Bell and Paterson (25, 
26) have recently reported that adjuvants are not necessary in the rat, whereas 
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Lee and Schneider (27) have demonstrated in mice that the relative amounts of 
brain and adjuvant are of critical importance. Our own results have indicated 
that both the neural and the adjuvant components are essential for the produc- 
tion of EAE in the guinea pig and that their relative proportions exert profound 
quantitative effects.  Furthermore, although briefly described earlier (28,  29), 
the fact that re]ativdy large amounts of adjuvant may mask the encephalito- 
genlc potential of only moderate amounts of neural tissue has riot been widely 
recognized in the past and may be of fundamental importance irt reconciling 
some of the discrepancies in the literature. 
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FIG. 1. Severity of EAE produced by various combinations of lyophilized homologous  brain 
and M. butyricum. The mean disease index  (maximally 9) for each group of five or more 
guinea pigs is plotted at the coordinates of the weights of each component contained in the 
0.1 mi of water-in-oil emulsion injected intracutaneously into each animal over the sternum. 
Methods 
Male guinea pigs of about 500 gm were obtained from two sources: in the experiments 
performed in Bethesda the closed but not inbred NIH stock of mixed colors was used, whereas 
in the experiments performed in Houston  and Seattle white but not inbred  animals were 
obtained from a single source (May Rabbitry, San Antonio). The animals were maintained 
under daily observation in the laboratory for 1 or 2 weeks before being challenged with an 
intracutaneous injection over the sternum of 0.1 ml of a vaccine containing brain in water- 
in-oil emulsion with killed mycobacteria. The vaccine contained  one part water,  one part 
aquaphor, and two parts light mineral oil (bayol F)  with a variable concentration of heat- 
killed, dry Mycobacterium butyricum or tuberculosis and variable  concentrations  of guinea 
pig brain or spinal cord. All weights are expressed as dry weights of mycobacteria, dry weights 
of lyophilized tissue, or equivalent dry weights of fresh spinal cord (based on a water con- 
tent of 70 per cent) contained in 0.I ml of the final vaccine. The vaccines were homogenized, 
heated to about 60°C, and emulsified by repeated aspiration and ejection through a syringe. 
Groups of at least five animals received the same vaccine. The animals were observed daily C-N[. SHAW,  E.  C. ALVORD,  JR., W.  J'. FAHLBERG,  AND  M.  W.  KIES  171 
for evidence of paralysis or other signs of EAE (30) and killed under nembutal  anesthesia 
by perfusion with 10 per cent formalin when moribund or at the end of the experiment (gen- 
erally 30 days after  challenge). The brain and spinal cord were embedded in paraffin, sec- 
tioned, and stained with hematoxylin and eosin. Comparison of the signs of EAE in vivo and 
post r,  tortem allowed the determination  of a numerical index of severity  of EAE (maximally 
10) for each animal and an average for each group (30). 
The day of onset of EAE was defined as the day of onset of definite paralysis or as the 
preceding day if questionable signs had been previously noted. The median day of onset for 
each group  (i.e., the day on which 50 per cent or more of the animals became sick) was not 
only the easiest to calculate but was also considered the most reliable since it was lea t in- 
fluenced by the more delayed cases, which are generally milder and more difficult to define 
precisely. 
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Fro. 2.  Severity of EAE (mean disease index) produced by various combinations of lyo- 
ph;1;~ed homologous brain and M. tuberculosis. 
RESULTS 
During  the past  7 years most of our studies  have been concerned with  the 
bio-assay  of encephalitogenic  fractions  of bovine  spinal  cord  and  guinea pig 
brain (31-34). In order to establish reference points for determining the relative 
activity of the fractions,  similar bio-assays have been made on various whole 
tissues  and  adjuvants  and  the  results  summarized  in  Figs.  1  and  2.  These 
figures are essentially three-dimensional  graphs and indicate,  by the numbers 
plotted  at  the  coordinates  of  particular  combinations  of  lyophilized  guinea 
pig brain with M. b~yr/cum (Fig. 1) or tubercuJosis  (Fig. 2), the average severity 
of EAE which resulted from intracutaneous  injection of a  vaccine containing 
that  combination  into  a  group  of five or more  guinea pigs.  (For  simplicity, 
only single digit numbers are used, 9  rather  than 10 thus becoming the maxi- 
mum).  The  dashed  lines  separate  those  combinations  which  produce  EAE 172  EXPERIMENTAL  ALLERGIC  ENCEPHALOMYELITIS 
from those which do not. The threshold for brain has not been sharply defined 
in Fig. 1 (0.03 to 0.1 rag), but in Fig. 2 is seen to be 0.03 to 0.05 mg. The thres- 
holds  for the  two  mycobacteria have  also  not been sharply defined, but  as 
little as 0.02 mg M. butyricum (Fig.  1) can be effective whereas the threshold 
for M. tuberculosis (Fig. 2) is probably closer to 0.1 mg. For both mycobacteria, 
however, large amounts no longer function effectively as adjuvant with small 
or moderate amounts of neural tissue. 
Fig.  3  summarizes  the  results  with  M.  tuberculosis  and  fresh  guinea  pig 
spinal  cord.  The dashed  line  indicates  the  combinations of  spinal  cord and 
adjuvant which will produce half-maximal disease and the solid line the com- 
binations which will produce maxima] EAE. The threshold for the spinal cord 
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FIo. 3. Severity of EAE (mean disease index) produced by various combinations of fresh 
homologous spinal cord (equivalent dry weight) and M. tuberculosis. 
is just below 0.06 nag,  but about ten times as much is required for maximal 
EAE. As little as 0.01 mg M. tuberculosis  can serve as adjuvant, but at least 
five times as much is required for maximal disease. As in the previous experi- 
ments  large  amounts  of  adjuvant  mask  the  encephalitogenic  potential  of 
moderate amounts of spinal  cord.  Only with large amounts  of neural  tissue 
does this masking effect disappear. 
A  horizontal  section  through  Fig.  3  at  the level of 2.5  mg  spinal  cord is 
given in Fig. 4,  which demonstrates the range of variation in the severity of 
EAE with variations in the amount of M. tuberculosis, the spinal cord concen- 
tration  being kept  constant  at  2.5  mg.  As  might  be  expected,  the  greatest 
variation occurs in  the region of the 50 per cent effective dose (EDs0)  of M. 
tuberculosis, which is about 0.01  mg. C-M.  SH.AW~ ~..  C.  ALVORD~ Jl~.} W.  J.  FAttLBER%  AND  M.  W.  KIES  173 
Fig. 5 is to be compared with Fig. 4 and gives the variation in median day 
of onset of paralysis after injection of the challenge vaccine  rather than the 
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FIG. 4.  Severity of EAE (mean disease index)  produced  by various amounts  of M.  lu- 
berculosis with 2.5 mg homologous spinal cord. 
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FIG. 5.  Severity of EAE (median day of onset of paralysis) produced by various amounts 
of M. tuberculosis with 2.5  mg homologous spinal cord.  (Base line at  * indicates less  than 
half the animals became paralyzed.) 
variation in disease index in these same  experiments.  With the combination 
used most frequently (2.5 mg spinal  cord and  1.0  nag M.  tuberculosis)  the 
median day of onset of EAE in groups of five or more guinea pigs was 11 to 13 
days in 46 of 56 experiments involving 405 guinea pigs. In only one experiment 
was the median day of onset delayed beyond 16 days after challenge. Since all 174  EXPERIM'ENTAL ALLERGIC ENCEPHALOM'YELITIS 
405  animals had histologic evidence of EAE,  this  vaccine can  be considered 
to contain a  100 per cent effective dose (ED10o); indeed,  only 25  guinea pigs 
failed to become paralyzed by the 17th day and only seven remained clinically 
well until  the 30th day. As a  result, in 98 per cent of the experiments half or 
more of the  guinea pigs had  become paralyzed by the  16th  day,  and  in  77 
per cent of the experiments all of the animals were paralyzed by the 19th day 
(Fig. 6). 
Within Figs. 3 to 6 are included results obtained with three different prepara- 
tions of pooled lots of three strains of M.  tuberculosis  (C,  DT, and PN),  ob- 
tained from three different sources  1 and suspended in oil for varying periods of 
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FIG. 6.  Day of onset for median (DOs0) and total  (DO,00) incidence of paralysis in 56 
experiments involving 405 guinea pigs given 2.5 mg homologous  spinal cord and 1.0 mg M. 
tuberculosis. 
time up to 3 months or more. Within the limited variations summarized above 
no  significant  differences  were  found  in  the  effectiveness  of  these  different 
preparations. 
DISCUSSION 
From the results presented in this paper and in the accompanying paper of 
Lee and Schneider  (27), it is apparent that the mouse and guinea pig require 
1  We wish to thank Dr. A. W. Tallman, Supt., Bacteriological Production Department, 
Lederle Laboratories, Pearl River, New York, and  Dr. J. V. Iron,  Director, Texas State 
Department of Health, Austin, for generously providing us with two preparations of steam- 
killed organisms. Smaller amounts of the same organisms, obtained from the Animal Inspec- 
tion and Quarantine Division, United States Department of Agriculture, were also prepared 
under similar conditions in the Department  of Microbiology, Baylor University College of 
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mycobacterial adjuvants for the production of EKE, whereas the rat may not 
(25, 26).  Furthermore, in the mouse (27) and guinea pig, a quantitative adju- 
vant effect can be demonstrated, and definite thresholds can be defined for 
both the neural and mycobacterial components of the encepha]itogenic vaccine. 
From the general shape of the boundaries defined in Fig. 3, it would appear 
that there is a  minimum amount of encephalitogenic tissue  (-4- 0.05  rag) for 
which a rather sharply defined amount of mycobacteria (4- 0.1 rag) is essential 
for the production of EAE. Smaller or larger amounts of mycobacteria do not 
bring  out  the  encephalitogenic potential of this  threshold  amount of spinal 
cord.  As  the  amount of encephalitogen is  increased,  however,  the  range  of 
mycobacterial content which can function as adjuvant broadens considerably 
(0.01 nag to 4 rag). In the mouse (27), on the other hand, there appears to be a 
linear  ratio  between the  amounts of encephalitogen and adjuvant which is 
critical for the production of EKE. Although the two species behave similarly 
with large amounts of adjuvant, they behave differently with small amounts 
of adjuvant. The significance of this discrepancy is not known. 
With the volume of vaccine constant at 0.1  ml, it becomes technically im- 
possible  to increase the amounts of either neural tissue or adjuvant beyond 
those shown in Figs.  1 to 3,  so that the upper boundaries, if any, cannot be 
determined.  If it were possible  to  extrapolate from the  data in  Fig.  3,  one 
would expect that with very large amounts of neural tissue EAE production 
in  the  guinea pig might become independent of the presence or amount of 
mycobacteria, which could then no longer be considered as an adjuvant. If 
this were correct, one might have an adequate frame of reference for including 
those cases of EAE produced in man or animals by brain-containing vaccines 
without adjuvants, especially since such cases generally occur infrequently and 
following large  doses  of neural  tissue.  An  alternative speculation might be 
that the lipids or other non-encephalitogenic components of brain may function 
as an adjuvant when present in sufficiently large  amounts.  Conversely, one 
would not  expect the  pure  encephalitogenic protein  to  have  such  adjuvant 
properties,  and  hence  it  should  not  be  encephalitogenic in  the  absence  of 
adjuvants no matter how much is used. 
Such speculations at first suggest a frame of reference for understanding why 
rats may develop EKE without adjuvants: perhaps rats are more susceptible 
to EKE. The fact that rats require over 30 times (18) as much neural tissue to 
become  paralyzed indicates,  however,  that  rats  cannot be  considered more 
susceptible  than  guinea pigs,  and  some  other  explanation must  be  sought. 
Levine  (35)  has  recently  observed  differences in  adjuvant  effectiveness in 
different strains of rats: some require mycobacteria and some do not. In either, 
however, adjuvants increase the incidence of EAE. He has attributed these 
differences to specific genetic differences, and such an hypothesis gains further 
support from data with the mouse, only a single strain of which appears to be 
susceptible to EAE (20). Although perhaps an adequate explanation for differ- 176  EXPERIMENTAL  ALLERGIC  ENCEPHALOM*CELn'Is 
ences between strains, it does not seem quite satisfactory for differences between 
species. 
In view of previous arguments regarding the importance of the day of onset 
of EAE (36) it may be of interest  to record here our belief that it is indeed a 
useful index of  the  intensity of EAE,  especially useful  when  one  wishes  to 
perform a  long series  of experiments,  each dependent  on  the  results  of  the 
previous ones. Within 2 to 3 weeks one can know the results with a high degree 
of accuracy and reproducibility, without waiting for the final results of histo- 
logic and statistical analysis (30). As with most short cuts, however, one must 
expect somewhat greater variability,  such  as  is  shown in  comparing  Figs.  4 
and 5. 
In all three species (rat, mouse, and guinea pig) the data are quite consistent 
in requiring central nervous tissue or specific extracts thereof for the production 
of EAE. In the guinea pig in particular we cannot give any confirmation for 
the reports that EAE can be produced without such specific encephalitogens 
(22-24). One can only suggest that such reports are due to the contamination 
of  the  experimental  animals  with  some  organism,  such  as  encephalitozoon 
cuniculi (37). 
The present experiments provide a  base line for the comparison of various 
adjuvants or encephalitogens. Such comparison may be made in terms of the 
amount which can produce half-maximal disease, i.e., the 50 per cent effective 
dose or EDs0  (30), but in actual practice the degree of variation in the results 
of the bio-assay is  so great  at  this  dose level that  comparisons  accurate  to 
within a factor of 5 are very difficult to obtain. Even within this range of error, 
however,  it  is  of interest  that  if  Freund's  "complete adjuvant"  is  used  as 
directed (7), 0.1  ml contains only 0.025  mg M. butyricum,  which is just about 
the threshold amount shown in Fig.  1 and is almost certainly suboptimal. In 
another paper  (38)  Freund  and  Lipton  used  ten  times  this  amount  of  M. 
tuberculosis (0.25 rag), which according to Fig. 3 is within the optimal range. 
When  one is  titrating  the  adjuvant,  one  must  not  only keep  the  neural 
component constant, but must also be careful to titrate the adjuvant over a 
wide enough range to avoid false negative results due to the use of too large 
an amount of adjuvant.  Such a  precaution was not used and may invalidate 
some of the negative results of White and Marshall  (39)  and Katsh (40) with 
various  types  and  extracts  of  mycobacteria.  This  masking  effect  may  be 
minimized, if not completely avoided, by using large amounts of encephalitogen, 
but such amounts are truly massive (2.5 mg spinal cord). 
The mechanism  of this  masking  effect of large  amounts of  mycobacterial 
adjuvant,  demonstrated  in  both  mouse  (27)  and  guinea  pig,  is  not known. 
Whether the physical state of the various emulsions is truly comparable cannot 
be stated,  but the masking  effect does not seem to be due to grossly visible 
differences in the degree of ulceration and sloughing out of the inoculum. It 
may be due to toxic factors (41) in the mycobacteria which modify or kill cells C-M.  SHAW,  E.  C.  ALVORD, JR.,  W.  J.  FAHLBERG,  AND  M.  W.  KIES  177 
more or less non-specifically,  or it may be due to specific competition of various 
antigens of the mycobacteria for the immunogenic mechanism at the expense 
of  the  relatively  smaller  amounts  of neural  antigens.  Support  for  this  last 
possibility is  given by the fact that  the masking  occurs with  the relatively 
non-toxic M. butyricum as well as with the relatively toxic M. tuberculosis. It 
becomes somewhat ¢l~cult,  however,  to  reconcile  this  masking  effect as  a 
competition of antigens with Burner's  (42) theory that sensitized  clones arise 
as spontaneous  mutants  which  are  selected out either  for proliferation  with 
relatively small doses of an antigen or for destruction by relatively large doses 
of antigen:  one would have to postulate that  a  significant  number of clones 
spontaneously arise specifically sensitive to antigens of both mycobacteria and 
brain. From this point of view the phenomenon of competition of antigens fits 
best with the theory that antigenic determinants a~tivdy induce sensitization 
of particular  clones  rather  than  pa~si~dy select out  those  which  arise  spon- 
taneously. 
SD'MM~xl~y 
Quantitative relationships between the amounts of encephalitogenic neural 
tissue and mycobacterial adjuvant are presented for the guinea pig, for com- 
parison with similar results obtained in the mouse and presented in an accom- 
panying paper by Lee and Schneider (27). Definite threshold amounts of both 
neural encephalitogenic and mycobacterial adjuvant can be defined.  With the 
proper amounts of each component, 100 per cent of guinea pigs can be made 
to develop EAE, 97 per cent dying of it, and over 50 per cent becoming para- 
lyzed by the 12th day after challenge.  With moderate amounts of encephall- 
togen the severity and incidence of EAE can be very great, but this encephall- 
togenic potential can be masked if large amounts of mycobacteria are employed. 
The mechanism of this masking effect by excess adjuvant is not known, but 
speculation  centers  upon  the  possibility of  competition  of  antigens  of  the 
mycobacteria at the expense of those of the encephalitogen. 
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